Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
UCB’s 90-year book is a goldmine to discover!
Twitter Feed
-
Dedicating your talent to push the boundaries of what is possible for patients today – that is what working at UCB is all about. #UCB90 https://t.co/xnfUepMf3Z
— UCB News (@ucb_news) 15.01.2019 -
UCB is proud to be part of the #WeWontRest campaign, an initiative by @EFPIA to highlight our shared commitment to solving the biggest problems in modern medicine. #Innovation #UCB90 https://t.co/FX0pbDoFf7 https://t.co/Bb60edsEsK
— UCB News (@ucb_news) 14.01.2019 -
We’re excited to be co-authors of a paper published in @EJNeuroscience which could help progress future treatments for Parkinson’s @EdinburghUni @crm_edinburgh @CureParkinsonsT https://t.co/yhavgDrk5e https://t.co/tgjwoOXmXG
— UCB News (@ucb_news) 09.01.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
